Cancer Advisor

For decades, chemotherapy was the backbone of cancer treatment. While chemotherapy can still save lives, a major shift is happening in oncology: immunotherapy is increasingly replacing — or dramatically reducing — the need for chemotherapy in selected cancers. Checkpoint inhibitors, CAR-T therapies, bispecific antibodies, tumor vaccines and precision immunotherapy combinations are changing survival outcomes once considered impossible. In some cancers, chemotherapy-free treatment is already becoming a new standard of care. Here are 10 cancers where immunotherapy is reshaping the future of treatment. 1. Melanoma Few cancers demonstrate the power of immunotherapy better than melanoma. Before checkpoint inhibitors, metastatic melanoma had extremely poor survival rates. Today, drugs targeting PD-1 and CTLA-4 have transformed outcomes for many patients. Examples include: Pembrolizumab Nivolumab Ipilimumab In many advanced melanoma cases: Immunotherapy is preferred before chemotherapy Durable...

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive biology, late diagnosis, and limited therapeutic options. Despite advances in multi-agent chemotherapy, the prognosis for metastatic disease remains poor. This review synthesizes current evidence on standard-of-care regimens, including NALIRIFOX and FOLFIRINOX, emerging targeted and immunotherapeutic approaches, and explores the potential repurposing of antiparasitic agents such as fenbendazole and ivermectin. We discuss recent clinical trials, safety profiles, and future directions for improving outcomes in stage 4 PDAC. Pancreatic Cancer Awareness Introduction Pancreatic cancer is among the most aggressive and therapeutically challenging malignancies, with a 5-year survival rate below 10% for all stages combined. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC) , which are frequently diagnosed at an advanced stage, limiting cura...